(Q34288517)

1 August 2017

title

Long term benefit of multiple sclerosis treatment: an investigation using a novel data collection technique (English)

1 reference

1 August 2017

0 references

1 reference

Devon S Conway

1

1 reference

1 August 2017

Deborah M Miller

series ordinal

2

1 reference

1 August 2017

Ralph G O'Brien

series ordinal

3

1 reference

1 August 2017

Jeffrey A Cohen

series ordinal

4

1 reference

1 August 2017

publication date

31 May 2012

1 reference

Multiple Sclerosis Journal

1 August 2017

published in

1 reference

1 August 2017

volume

18

1 reference

1 August 2017

issue

11

1 reference

1 August 2017

page(s)

1617-1624

1 reference

Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458512449681

Reliability and validity of two self-report measures of impairment and disability for MS. North American Research Consortium on Multiple Sclerosis Outcomes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512449681

Validity of performance scales for disability assessment in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512449681

The Multiple Sclerosis Functional Composite: a new clinical outcome measure for multiple sclerosis trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512449681

The multiple sclerosis functional composite: a clinically meaningful measure of disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512449681

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512449681

New perspectives in the natural history of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512449681

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512449681

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512449681

Estimating causal effects from large data sets using propensity scores

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512449681

A Multiple Comparison Procedure for Comparing Several Treatments with a Control

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512449681

Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512449681

PRISMS: the story of a pivotal clinical trial series in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512449681

Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512449681

Factors associated with a rapid course of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512449681

Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512449681

Real-life impact of early interferon beta therapy in relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512449681

Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512449681

Natural history of multiple sclerosis in a population-based cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512449681

Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512449681

The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512449681

Evidence for a two-stage disability progression in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512449681

Emerging effects of comorbidities on multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512449681

Natural history of secondary-progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512449681

21 January 2018

Identifiers

DOI

10.1177/1352458512449681

1 reference

1 August 2017

1 reference